Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc.
Opinion
Case: 23-1169 Document: 82 Page: 1 Filed: 07/15/2026
NOTE: This order is nonprecedential.
United States Court of Appeals for the Federal Circuit ______________________
AMARIN PHARMA, INC., AMARIN
PHARMACEUTICALS IRELAND LIMITED,
MOCHIDA PHARMACEUTICAL CO., LTD.,
Plaintiffs-Appellants v.
HIKMA PHARMACEUTICALS USA INC., HIKMA PHARMACEUTICALS PLC,
Defendants-Appellees
HEALTH NET LLC,
Defendant ______________________
2023-1169 ______________________
Appeal from the United States District Court for the District of Delaware in No. 1:20-cv-01630-RGA-JLH, Judge Richard G. Andrews. ______________________ SUA SPONTE ______________________
Before MOORE, Chief Judge, MAYER and LOURIE, Circuit Judges ______________________ Case: 23-1169 Document: 82 Page: 2 Filed: 07/15/2026
2 AMARIN PHARMA, INC. v. HIKMA PHARMACEUTICALS USA INC.
PER CURIAM.
ORDER
Upon consideration of the judgment of the Supreme Court of the United States in Hikma Pharmaceuticals USA Inc., et al. v. Amarin Pharma, Inc., et al., No. 24-889, IT IS ORDERED THAT:
The mandate of this court that issued October 24, 2024, is recalled, the appeal is reinstated, and this court’s June 25, 2024, opinion and judgment are vacated. We further remand this case to the United States District Court for the District of Delaware for further proceedings consistent with the Supreme Court’s decision.
FOR THE COURT
July 15, 2026
Date
Case-law data current through September 30, 2026. Source: CourtListener bulk data.